Nanogen exits array business
This article was originally published in The Gray Sheet
Executive Summary
Nanogen plans to close its array business and cut 20% of its staff to save about $15 million. The company originally announced it was considering dropping the business in September (1"The Gray Sheet" Sept. 24, 2007, p. 14). "Our analysis of alternatives for the array business has not resulted in any financially meaningful opportunities," COO David Ludvigson said Nov. 12. "The best way to meet our commitment to improving financial performance for our shareholders is to focus on our real-time PCR and point-of-care testing businesses." The restructuring will cost $6.9 million, charged to the third quarter, for inventory and assets related to the array business and $2.5 million in severance costs charged to the fourth quarter. The company will continue to supply most cartridges for the NanoChip electronic microarray system to customers through 2008
You may also be interested in...
Diagnostics In Brief
First genetic test for warfarin sensitivity cleared: Nanosphere's Verigene multiplex nucleic acid test for genetic variations that influence metabolism of the common blood-thinner warfarin is 510(k)-cleared Sept. 17. FDA updated the labeling of warfarin in August to explain that patients with variations in the CYP2C9 and VKORC1 genes may respond differently to the drug (1"The Gray Sheet" Aug. 20, 2007, p. 9). Other firms developing warfarin test kits include AutoGenomics, Nanogen, Third Wave Technologies and Luminex
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.